We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Assembly Biosciences (ASMB - Free Report) shares rallied 24% in the last trading session to close at $14.18. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 22.9% gain over the past four weeks.
The company has four developmental candidates that are being investigated in early-stage studies for treating chronic infections like herpesvirus, hepatitis B virus and hepatitis delta virus. Several clinical data readouts are expected later in 2025. The growing optimism related to the rapid progress of Assembly Biosciences’ antiviral pipeline might have driven the recent share price rally.
This biotech drug developer is expected to post quarterly loss of $2.01 per share in its upcoming report, which represents a year-over-year change of -21.1%. Revenues are expected to be $7.76 million, up 34% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Assembly Biosciences, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ASMB going forward to see if this recent jump can turn into more strength down the road.
Assembly Biosciences belongs to the Zacks Medical - Generic Drugs industry. Another stock from the same industry, Taysha Gene Therapies, Inc. (TSHA - Free Report) , closed the last trading session 7.1% higher at $2.58. Over the past month, TSHA has returned 91.3%.
Taysha Gene Therapies' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.08. Compared to the company's year-ago EPS, this represents a change of +20%. Taysha Gene Therapies currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?
Assembly Biosciences (ASMB - Free Report) shares rallied 24% in the last trading session to close at $14.18. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 22.9% gain over the past four weeks.
The company has four developmental candidates that are being investigated in early-stage studies for treating chronic infections like herpesvirus, hepatitis B virus and hepatitis delta virus. Several clinical data readouts are expected later in 2025. The growing optimism related to the rapid progress of Assembly Biosciences’ antiviral pipeline might have driven the recent share price rally.
This biotech drug developer is expected to post quarterly loss of $2.01 per share in its upcoming report, which represents a year-over-year change of -21.1%. Revenues are expected to be $7.76 million, up 34% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Assembly Biosciences, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ASMB going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Assembly Biosciences belongs to the Zacks Medical - Generic Drugs industry. Another stock from the same industry, Taysha Gene Therapies, Inc. (TSHA - Free Report) , closed the last trading session 7.1% higher at $2.58. Over the past month, TSHA has returned 91.3%.
Taysha Gene Therapies' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.08. Compared to the company's year-ago EPS, this represents a change of +20%. Taysha Gene Therapies currently boasts a Zacks Rank of #3 (Hold).